Health Care's Sweet 16 Stocks: Novartis vs. Bristol-Myers Squibb

Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means Cinderella stories like Florida Gulf Coast have busted the brackets of would-be prognosticators.

Here at The Motley Fool, we decided to stick with what we know, trading our basketball picks in for stock picks. We formed our own Sweet 16 filled with the top Big Pharma and Big Biotech stocks in a winner take-all tournament determined by the collective intelligence of our CAPS community.

This matchup will feature a heavyweight bout between Novartis and Bristol-Myers Squibb. Watch and find out which stock gets eliminated and which will advance to the next round.

Is bigger really better?Involved in everything from baby powder to biotech, Johnson & Johnson has its critics convinced that the company is spread way too thin. If you want to know whether J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out the Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.